GLP-1 drug comparison claims: what the evidence actually shows

What did @obesitydrdannak actually say?

Dr. Dana gave a quick-hit breakdown of the major FDA-approved GLP-1 medications, walking viewers through daily versus weekly injectables, the brand-name split between diabetes and weight loss indications, oral options, and a newer drug she called "the least effective option." She framed liraglutide as the original GLP-1, semaglutide (Ozempic/Wegovy) as widely known but not the most potent, and tirzepatide (Mounjaro/Zepbound) as the current top performer. She closed by noting she was only covering FDA-approved drugs.

The framing is useful for a general audience. Running through six drugs in under two minutes means some nuance gets cut. That's worth examining closely, because a few of those cuts land closer to oversimplification than shorthand.

Does the science back this up?

Mostly, yes, with some important asterisks. The hierarchy she lays out, where tirzepatide outperforms semaglutide outperforms liraglutide, is broadly supported by head-to-head and comparative trial data. But "most effective" is doing a lot of work in a short video.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at its highest dose produced mean weight loss of about 22.5% of body weight over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced roughly 14.9% weight loss. Liraglutide's SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) showed about 8% weight loss at 3mg. So the ranking holds. However, calling tirzepatide "most effective" glosses over the fact that individual response varies substantially, and no trial has directly compared all three in the same population under the same conditions.

On oral semaglutide (Rybelsus versus oral Wegovy), the bioavailability differences are real. The OASIS 1 trial (Lau et al., 2023, The Lancet) confirmed oral semaglutide 50mg produced about 15.1% weight loss, comparable to injectable Wegovy in some analyses, though the dosing ceiling and formulation constraints still matter clinically.

What did they get wrong (or right)?

The Ozempic/Wegovy explanation is largely right. Same active ingredient, semaglutide, different approved indications and dosing. Ozempic tops out at 2mg weekly for type 2 diabetes. Wegovy goes to 2.4mg weekly for chronic weight management. Dr. Dana's point that "the dosing does differ" is accurate and often missed in casual conversation.

Same logic applies to Mounjaro versus Zepbound. Tirzepatide is tirzepatide. The brand split is regulatory and commercial, not pharmacological. She gets that right.

Where it gets murkier: she calls Cagrilintide (which sounds like what she was mispronouncing as "soundeo" or "Iqsymia") the least effective and says it doesn't work the same way. If she was referring to semaglutide plus cagrilintide combination or a separate amylin-based agent, that drug is not currently FDA-approved for weight management as a standalone. Her disclaimer that she's only covering FDA-approved drugs is good practice, but the identification of the drug she was referencing was unclear enough in the transcript to make verification difficult.

Calling liraglutide "Loraglotide" and Saxenda "Sicenda" are phonetic stumbles, not factual errors, but in a medical education video, precision matters.

What should you actually know?

The GLP-1 class is not one-size-fits-all, and "most effective" is a population-level stat, not a personal prediction. Tirzepatide is a dual GIP/GLP-1 receptor agonist, which is mechanistically different from pure GLP-1 agonists like semaglutide or liraglutide. That distinction matters for how it works and likely for its side effect profile, though head-to-head tolerability data is still thin.

Insurance coverage, cost, and individual tolerance often matter more than trial averages when deciding which drug someone actually stays on. A drug that produces 22% weight loss in a trial means nothing if a patient discontinues it at week six due to nausea. Persistence rates are a real clinical variable that short-form content rarely addresses.

The oral versus injectable bioavailability gap is also worth understanding. Oral semaglutide requires very specific dosing conditions, taken fasting with a small amount of water, and its absorption is sensitive to food and other medications. That's not a minor footnote.

Anyone seeing content like this should treat it as orientation, not a prescription guide. A licensed clinician who knows your full health history should be making the actual call on which agent, if any, is appropriate for you.